This article first appeared on GuruFocus. Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) is set to release its Q3 2026 earnings on Jan 30, 2026. The consensus estimate for Q3 2026 revenue is $6.66 billion, and ...
Dr Lal Pathlabs Ltd recorded volume of 8.65 lakh shares by 10:47 IST on BSE, a 104.67 times surge over two-week average daily volume of 8262 shares ...
Dr. Lal PathLabs is lining up a decisive acquisition drive to consolidate India’s hyper‑local diagnostics market, with Group CFO and International CEO Ved Goel signalling that the company is now “a ...
Dr. Lal Path Labs posts earnings dip on Indian labour code changes; test demand strong Dr. Lal Path Labs reported a lower third-quarter profit on Friday after taking a one-time charge linked to ...
Diagnostics company Dr Lal PathLabs rose as much as 8.18 per cent to the day's high of Rs 2,540 on NSE in morning deals.
New Delhi-headquartered Dr Lal PathLabs reported a 49 per cent year-on-year jump in consolidated net profit to Rs 84.5 crore ...
An Indian health official uses a swab to collect sample from a woman to conduct tests for the coronavirus disease (COVID-19), amid the spread of the disease, at Nehru Homoeopathic Medical College and ...
BENGALURU, May 11 (Reuters) - India's Dr. Lal PathLabs Ltd (DLPA.NS), opens new tab on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from COVID-related ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results